Opipramol, sold under the brand name Insidon among others, is an anxiolytic and tricyclic antidepressant that is used throughout Europe. It is a dibenzazepine-derivative with predominant clinical action mediated through sigma receptor modulation and antagonism at several aminergic receptors rather than strong monoamine reuptake inhibition typical of many other tricyclics. The molecule is orally active, undergoes hepatic metabolism with formation of dealkylated and oxidized metabolites, and has dose-dependent sedative and anxiolytic effects; typical therapeutic dosing is titrated to clinical response and commonly ranges within low hundreds of milligrams per day administered once or in divided doses. Clinically opipramol is used for generalized anxiety, somatoform disorders, and as an adjunct for depressive symptoms where anxiety or sleep disturbance is a prominent feature. Safety considerations include anticholinergic, antihistaminic and alpha-adrenergic effects, potential pharmacodynamic interactions with other CNS depressants, and the need for dose adjustment or monitoring in hepatic impairment.
Parent: Opipramol
![5-(3-Chloropropyl)-5H-dibenzo[b,f]azepine](https://veeprho.com/wp-content/uploads/2025/01/VE0022913-Opipramol-Impurity.png "5-(3-Chloropropyl)-5H-dibenzo[b,f]azepine")
Parent: Opipramol
The impurity profile for opipramol includes related substances arising from raw material residues, synthetic intermediates and drug metabolism, commonly reported species are N-desalkyl-opipramol (desmethyl derivative), N-oxide metabolites, minor ring-hydroxylated products and trace deamination or dealkylation products; these are typical targets for identification and quantification during quality control. In practice manufacturers set limits for individual specified impurities at low subpercent levels and control unidentified or unspecified impurities to meet pharmacopeial and ICH expectations; commonly accepted control ranges for commercial active pharmaceutical ingredients are individual identified impurities controlled to approximately 0.1 to 0.5 percent by weight and total related substances controlled to roughly 1.0 to 3.0 percent by weight depending on the impurity qualification status and regulatory requirements. Analytical methods used include HPLC with appropriate stability-indicating conditions, mass spectrometry for peak identification and validated limits for reporting, identification and qualification in support of product registration.
Opipramol is used primarily to treat anxiety disorders, somatoform and psychosomatic conditions and for relief of associated depressive symptoms and sleep disturbance where sedation is desirable.
No, Opipramol is not a benzodiazepine. It is a tricyclic dibenzazepine derivative with a different receptor profile and pharmacology from benzodiazepines.
Opipramol can improve sleep for patients whose insomnia is linked to anxiety because it has sedative properties; it is not classified as a primary hypnotic but may help sleep initiation and continuity in clinical practice.
Weight change can occur with many tricyclic-type agents and some patients taking opipramol report modest weight gain; risk varies by individual and should be monitored during treatment.
